tiprankstipranks
Open Orphan Plc Triumphs in RSV Antiviral Trial
Company Announcements

Open Orphan Plc Triumphs in RSV Antiviral Trial

Open Orphan Plc (GB:HVO) has released an update.

Don't Miss Our Christmas Offers:

Open Orphan Plc, a leading contract research organization, has announced positive results from a Phase 2a RSV human challenge trial for Enanta Pharmaceuticals’ antiviral candidate EDP-323. The trial demonstrated the candidate’s safety, tolerability, and significant antiviral effect in reducing viral load and clinical symptoms in healthy adults. hVIVO’s expertise in human challenge trials continues to support the accelerated development of respiratory disease treatments.

For further insights into GB:HVO stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskhVIVO’s Landmark COVID-19 Study Published in Nature Communications
TipRanks UK Auto-Generated NewsdeskhVIVO Clinches Major Contract for RSV Challenge Trials
TipRanks UK Auto-Generated NewsdeskOctopus Investments Increases Stake in hVIVO PLC
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App